Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

Figures & data

Table 1 Baseline characteristics of eyes in study

Variables	N=45
Affected eye (right:left)	24:21
Mean duration of active CSR (months)	7.6 (±9.7)
Mean follow-up (mo)	19.3 (±13.0)
BCVA (logMAR, Snellen)
Baseline	0.52, 20/66
CRT (μm)
Baseline	349 (±119)
CT (μm)
Baseline	311 (±43)
SRF present (n)
Baseline	45
Initial follow-up	15
Final	4

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; CSR, central serous retinopathy; CT, choroidal thickness; SRF, subretinal fluid.

Figure 1 Mean BCVA at baseline and both follow-ups, showing significant improvement over time.

Note: Error bars represent standard errors of the mean.
Abbreviation: BCVA, best-corrected visual acuity.

Figure 2 Resolution of subretinal fluid with treatment over time.

Abbreviations: PDT, photodynamic therapy; SRF, subretinal fluid.

Figure 3 Mean central retinal thickness at baseline and both follow-ups, showing significant reduction with treatment.

Abbreviation: CRT, central retinal thickness.

Figure 4 Mean choroidal thickness at baseline and both follow-ups, showing significant reduction with treatment.

Abbreviation: CT, choroidal thickness.